Human vaccines are available for both bacterial and viral diseases. Human vaccines can be rendered into the body by aerosol, injections or orally. Vaccines contain agents that resemble microorganisms that cause disease. However, to prevent them from causing disease, microbial parts, weakened microbes, or dead microbes are infused in the vaccines. When vaccines are infused into the body, the immune system of the individual will resist the harmless germs, and swiftly remove them from the body. This process will improve the immune power of the body.
Attenuated vaccines, combination vaccines, conjugate vaccines, DNA vaccines, inactivated vaccines, recombinant vector vaccines, subunit vaccines and toxoid vaccines are some major types of human vaccines. Human vaccines find application against illnesses such as chickenpox, diphtheria, hepatitis, hepatitis, humanpaillomavirus, influenza, measles, meningococcal, mumps, polio, pertussis, pneumococcal, rabies, rotavirus, smallpox, tetanus, yellow fever, zoster and some others. Human vaccines are available for adolescents, adults, geriatric and pediatric age groups.
The high occurrence of various viral and bacterial diseases are driving the growth of the global human vaccines market. The intervention of governments as well as other non-governmental agencies through various awareness campaigns is aiding the increasing awareness about the benefits of human vaccines among the public worldwide. The increase in awareness is expected to enhance the growth of the human vaccines market, as it prompts more people to seek vaccinations.
The compulsory and non-compulsory vaccination as part of immunisation programmes for children against certain diseases are expected to drive the growth of the global human vaccines market, as these vaccines are essential to prevent some of the eradicated diseases from re-emerging. Minimal or low occurrence of fatal or serious side effects related to human vaccines as per the age group, paediatric segment accounts for more than 50% of the overall human vaccines demand.
Among the vaccine products, pneumococcal segment accounts for significant market share. Combination human vaccines are expected to attain considerable growth during the forecast period. As there are minimal or relatively low risk of serious or fatal side effects related to the human vaccines people are now more open to the use of vaccines. Moreover, the assurance from major health organisations such as WHO and AMA, drives the adoption of human vaccines significantly and it is expected to drive the growth of the global human vaccines market during the forecast period.
Stringent regulations set by various countries and high costs associated with research and development, manufacturing, handling, storage and transportation are the major challenges for the major players in the global human vaccines market. The technical expertise and patents by a few players in the market are among the challenges for the new entrants in this market; moreover, it requires a huge investments for new players to enter the market. These are expected to remain as the major restraints for the global human vaccines market during the forecast period.
Due to the intense competition, mergers and acquisitions are expected to be a pathway for major players for consolidation in the global human vaccines market during the forecast period. Opportunities are expected to be there for the major players to expand in the developing and poor economies as governments focus on immunisation programmes against various diseases during the forecast period.
The report segments the global human vaccines market by product, disease condition and region. On the basis of product, the market is segmented as live attenuated vaccines, killed vaccines, conjugate vaccines, and synthetic vaccines. Based on disease condition, the market is segmented as pneumonia, influenza, hepatitis, HPV and others.
Geographic Coverage and Analysis:
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. North America leads the global human vaccines market due to the increasing number of patients with cancers. Furthermore, infectious diseases are increasing considerably in countries such as Canada and USA. Huge investments from governments for vaccine research and immunization programmes drive the North American human vaccines market. Presence of major pharmaceutical companies’ research & development and production facilities of human vaccines drive the European region as the second largest human vaccines market.
Significant portion of the human vaccines manufactured in Europe are exported to other regions. However, the vaccination programmes conducted by various healthcare services in European countries drive the demand for human vaccines in European region. The presence of large population in countries such as China and India drive the growth of Asia-Pacific human vaccines market. Asia-Pacific region is expected to emerge as the fastest growing market due to the government support and investment in the immunization programmes in various countries. Latin American region is expected to experience a surge in demand for human vaccines for cancer and various infectious diseases.
African region relies heavily on UNICEF for human vaccines as they are heavily subsidized. African market present opportunity for expansion for major human vaccines manufacturers, as there is scope for immunization programmes for various diseases. Increasing demand for polio, pertussis and influenza vaccines is expected to drive the growth of the Middle East human vaccines market during the forecast period.
- CSL Limited,
- GlaxoSmithKline PLC,
- Merck & Co. Inc.,
- Novartis AG,
- Pfizer Inc.,
- Takeda Pharmaceutical Company Limited.,
- Emergent BioSolutions Inc.,
- Bavarian Nordic,
- Sanofi Pasteur
- Serum Institute of India Pvt Ltd.
The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the demand of human vaccines globally as well as regionally. Moreover, the author's Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter’s five forces analysis of human vaccines market. Moreover, the study highlights current market trends and provides forecast from 2017 to 2021.
We also have highlighted future trends in the human vaccines market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight on the market share of the leading players. Additionally, the analysis highlights rise and fall in the market shares of the key players in the market. This report will help manufacturers, suppliers and distributors of the human vaccines market to understand the present and future trends in this market and formulate their strategies accordingly.
1.1 Report Description
1.2 Research Methods
1.3 Research Approaches
2. Executive Summary
3. Global Human Vaccines Market Overview
3.2 Market Dynamics
3.3 Porter’s Five Forces Analysis
3.4 Growth Matrix Analysis
3.5 Competitive Landscape in the Human Vaccines Market
4. Global Human Vaccines Market Analysis, by Product (USD Million, KT) 2017-2023
4.1 Live Attenuated Vaccines
4.2 Killed Vaccines
4.3 Conjugate Vaccines
4.4 Synthetic Vaccines
5. Global Human Vaccines Market Analysis, by Disease Condition (USD Million, KT) 2017-2023
6. Global Human Vaccines Market Analysis, by Region (USD Million, KT) 2017-2023
6.1 North America
6.1.1 North America Human Vaccines Market by Product type (USD Million, KT)
6.1.2 North America Human Vaccines Market by disease condition (USD Million, KT)
6.2.1 Europe Human Vaccines Market by Product type (USD Million, KT)
6.2.2 Europe Human Vaccines Market by disease condition (USD Million, KT)
6.3.1 Asia-Pacific Human Vaccines Market by Product type USD Million, KT)
6.3.2 Asia-Pacific Human Vaccines Market by disease condition (USD Million, KT)
6.4 Rest of the World (RoW)
6.4.1 RoW Human Vaccines Market by Product type (USD Million, KT)
6.4.2 RoW Human Vaccines Market by disease condition (USD Million, KT)
7. Company Profiles
7.1 CSL Limited
7.2 GlaxoSmithKline Plc
7.3 Merck & Co., Inc.
7.4 Novartis AG
7.5 Pfizer, Inc.
7.6 Tadeka Pharmaceutical Company Limited
7.7 Emergent BioSolutions, Inc.
7.8 Bavarian Nordic
7.9 Sanofi Pasteur
7.10 Serum Institute of India Pvt Ltd